Hi Charlie,

I’m writing to share some very good news with you, your team, and AcceleDev. Today we received news that the FDA has approved Gavreto (BLU-667) for the treatment of RET Fusion-Positive Non-Small Cell Lung Cancer. Here is a link to the press release:

http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-fda-approval-gavretotm-pralsetinib

You and your team have been with this program from the beginning, from making a key building block at massive scale, to the transition to the synthesis of the more advanced material. There are been countless times we have been in a bind for material and you and the entire Acceledev team pull together and commit to the intense timelines that Blueprint seems to demand.  As we go into commercial, we continue our relationship with AcceleDev in our commitment to solid science for the betterment of all the patients in need.

Today you should all feel very proud that your hard work. Material produced by the talented and dedicated team at AcceleDev has been and continues to be used to make a difference in people’s lives.  I’m attaching a couple of links to articles about 2 patients who are being treated with Gavreto:

https://ascopost.com/issues/july-25-2020/a-diagnosis-of-advanced-lung-cancer-is-no-longer-a-death-sentence/

https://www.mdanderson.org/cancerwise/thanks-to-targeted-therapy-clinical-trial–lung-cancer-survivor-is-enjoying-life-again.h00-159384312.html

Thank you all!

Josh P.

Customer from Medium U.S. Pharma